摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Methyl-pentanthiol-(2) | 1639-05-0

中文名称
——
中文别名
——
英文名称
4-Methyl-pentanthiol-(2)
英文别名
2-Pentanethiol, 4-methyl-;4-methylpentane-2-thiol
4-Methyl-pentanthiol-(2)化学式
CAS
1639-05-0
化学式
C6H14S
mdl
——
分子量
118.243
InChiKey
JBCIMWBQDMBMMP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    -113.76°C (estimate)
  • 沸点:
    150.86°C (estimate)
  • 密度:
    0.8408 (estimate)

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    7
  • 可旋转键数:
    2
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    1
  • 氢给体数:
    1
  • 氢受体数:
    1

SDS

SDS:1c0870de0be840b65d853640cda8ddf0
查看

反应信息

  • 作为反应物:
    描述:
    4-Methyl-pentanthiol-(2)溶剂黄146 作用下, 生成 2-Methylpentan-4-sulfochlorid
    参考文献:
    名称:
    THE PREPARATION OF ALKANESULFONYL HALIDES
    摘要:
    DOI:
    10.1021/jo01144a013
  • 作为产物:
    描述:
    alkaline earth salt of/the/ methylsulfuric acid 在 乙醇potassium hydrosulfide 作用下, 生成 4-Methyl-pentanthiol-(2)
    参考文献:
    名称:
    Laparoscopic or Open Cholecystectomy in Patients with Sickle Cell Disease: which Approach is Superior?
    摘要:
    目的:比较腹腔镜与开腹胆囊切除术在镰状细胞病患者中的应用。设计:回顾性临床研究。机构:希腊大学医院。对象:1991年9月至1998年6月,41名镰状细胞病患者(22名男性和19名女性)接受了腹腔镜胆囊切除术。每位患者与接受开腹胆囊切除术的镰状细胞病患者按年龄、性别、手术年份和术前输血次数进行匹配对照。主要结局指标:手术时间、术后住院时间、并发症发生率和转为开腹手术。结果:开腹胆囊切除术的平均手术时间为81.4分钟(范围55-125分钟),腹腔镜胆囊切除术的平均手术时间为64.2分钟(范围45-90分钟)(p < 0.01)。腹腔镜组5%(2/41)的患者和开腹组20%(8/41)的患者发生并发症(p = 0.04)。开腹组的平均住院时间为5.6天(范围3-9天),腹腔镜组的平均住院时间为2.7天(范围2-5天)(p < 0.01)。2名(5%)患者需要转为开腹手术。结论:在镰状细胞病患者中,腹腔镜胆囊切除术导致住院时间更短且术后并发症更少,可能是这类患者胆石症治疗的首选手术方式。
    DOI:
    10.1080/110241500447236
点击查看最新优质反应信息

文献信息

  • SUBSTITUTED ARYL AND HETEROARYL CARBOXYLIC ACID HYDRAZIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS
    申请人:BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    公开号:US20180206495A1
    公开(公告)日:2018-07-26
    Substituted aryl- and heteroarylcarbonyl hydrazides The invention relates to substituted aryl- and heteroarylcarbonyl hydrazides of the general formula (I) or salts thereof where the radicals of the formula (I) are each as defined in the description for enhancing stress tolerance in plants to abiotic stress, and for enhancing plant growth and/or for increasing plant yield.
    该发明涉及通式(I)的取代芳基和杂芳基羰基肼或其盐,其中通式(I)的基团如描述中所定义,用于增强植物对非生物胁迫的耐受性,促进植物生长和/或增加植物产量。
  • Novel pyridine derivative and pyrimidine derivative
    申请人:Matsushima Tomohiro
    公开号:US20050277652A1
    公开(公告)日:2005-12-15
    A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R 1 represents C 1-6 alkyl or the like; R 2 and R 3 represent hydrogen; R 4 , R 5 , R 6 , and R 7 may be the same or different and each represents hydrogen, halogen, C 1-6 alkyl or the like; R 8 represents hydrogen or the like; R 9 represents C 1-6 alkyl or the like; V 1 represents oxygen or the like; V 2 represents oxygen or sulfur; W represents —NH— or the like; X represents —CH═, nitrogen or the like; and Y represents oxygen or the like.]
    以下化合物的分子式,其盐或前述水合物具有出色的肝细胞生长因子受体(HGFR)抑制活性,并表现出抗肿瘤活性、抑制血管生成活性和抑制癌转移活性。 [R 1 代表C 1-6 烷基或类似物;R 2 和R 3 代表氢;R 4 ,R 5 ,R 6 和R 7 可以相同也可以不同,每个代表氢、卤素、C 1-6 烷基或类似物;R 8 代表氢或类似物;R 9 代表C 1-6 烷基或类似物;V 1 代表氧或类似物;V 2 代表氧或硫;W代表—NH—或类似物;X代表—CH═、氮或类似物;Y代表氧或类似物。]
  • [EN] ISOXAZOLINE COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS<br/>[FR] COMPOSÉS ISOXAZOLINE ET LEUR UTILISATION EN TANT QU'AGENTS DE LUTTE CONTRE LES ORGANISMES NUISIBLES
    申请人:PI INDUSTRIES LTD
    公开号:WO2021038501A1
    公开(公告)日:2021-03-04
    The present invention discloses an isoxazoline compound of formula (I), wherein, R1, R2a, R2b, R2c, A, T and Z are as defined in the detailed description. The present invention further discloses methods for preparation of compounds of formula (I) and use of the compounds of formula (I) as a pest control agents.
    本发明公开了一种式(I)的异氧杂环烷化合物,其中,R1、R2a、R2b、R2c、A、T和Z如详细说明中所定义。本发明还公开了制备式(I)化合物的方法以及将式(I)化合物用作杀虫剂的用途。
  • [EN] FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF<br/>[FR] DERIVES DE LA PYRIMIDIN-4(3H)-ONE A CYCLES FUSIONNES, SPN PROCEDE DE PREPARATION ET SES UTILISATIONS
    申请人:SANKYO CO
    公开号:WO2003106435A1
    公开(公告)日:2003-12-24
    AbstractNovel compounds of the following formula (I) and pharmacologically acceptable salt and esters thereof can modulate LXR function and as a result show excellent anti-arteriosclerotic and anti-inflammatory activity:wherein:A represents aryl or heteroaryl;R1, R2 and R3 are the same or different and each represents hydrogen, hydroxyl, nitro, cyano, amino, halogen, carboxy, carbamoyl, mercapto, alkyl, haloalkyl, alkylcarbonyloxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino, alkylcarbonylamino, N-(alkylcarbonyl)-N-(alkyl)amino, alkoxycarbonylamino, N-(alkoxycarbonyl)-N-(alkyl)amino, alkylsulfonylamino, N-(alkylsulfonyl)-N-(alkyl)amino, haloalkylsulfonylamino, N-(haloalkylsulfonyl)-N-(alkyl)amino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl group, or R1 and R2 together are alkylenedioxy;R4 and R5 are the same or different and each represents hydrogen, hydroxyl, amino, halogen, mercapto, alkyl, haloalkyl, alkoxy, alkoxycarbonyl or alkylthio;X represents hydrogen, hydroxyl, halogen, alkoxy or haloalkoxy; andY represents an optionally substituted alkyl, cycloalkyl, heterocyclyl, aryl, cycloalkylalkyl, heterocyclylalkyl or aralkyl group.
    新化合物具有以下式(I)的结构,其药学上可接受的盐和酯可以调节LXR功能,从而表现出优秀的抗动脉粥样硬化和抗炎活性:其中:A代表芳基或杂环芳基;R1、R2和R3相同或不同,每个代表氢、羟基、硝基、氰基、氨基、卤素、羧基、氨基甲酰基、巯基、烷基、卤代烷基、烷基羰氧基、烷氧基、烷硫基、烷磺基、烷基氨基、二烷基氨基、烷基羰基氨基、N-(烷基羰基)-N-(烷基)氨基、烷氧羰基氨基、N-(烷氧羰基)-N-(烷基)氨基、烷磺酰氨基、N-(烷磺酰基)-N-(烷基)氨基、卤代烷基磺酰氨基、N-(卤代烷基磺酰基)-N-(烷基)氨基、烷基羰基、烷氧羰基、烷基氨基羰基或二烷基氨基羰基,或R1和R2一起是亚烷二氧基;R4和R5相同或不同,每个代表氢、羟基、氨基、卤素、巯基、烷基、卤代烷基、烷氧基、烷氧羰基或烷硫基;X代表氢、羟基、卤素、烷氧基或卤代烷氧基;Y代表可选择取代的烷基、环烷基、杂环烷基、芳基、环烷基烷基、杂环烷基烷基或芳基烷基。
  • Novel piperidine compouds and drugs containing the same
    申请人:——
    公开号:US20030220368A1
    公开(公告)日:2003-11-27
    The present invention provides a novel compound having a superior Na + channel inhibition activity. Namely, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them. 1 In the formula, the ring A represents a ring represented by the formula: 2 (wherein R 1 represents a hydrogen atom etc.; and R 2 represents indicates a hydrogen atom and the like) etc.; W represents an optionally substituted C 1-6 alkylene group etc.; Z represents an optionally substituted C 6-14 aromatic hydrocarbon cyclic group etc.; and l represents an integer from 0 to 6.
    本发明提供了一种具有优越的Na + 通道抑制活性的新型化合物。即提供了由以下式(I)表示的化合物,其盐或其水合物。 在该式中,环A表示由以下式表示的环: (其中R 1 表示氢原子等;R 2 表示表示氢原子等)等;W表示可选地取代的C 1-6 烷基等;Z表示可选地取代的C 6-14 芳香烃环基等;l表示0到6的整数。
查看更多